Sartorius New Software Solution for Pharma Industry
Sartorius Stedim Biotech (SSB), a leading global supplier to the biopharmaceutical industry, announced the launch of Active Dashboard 2, an advanced software solution.
Offered by its subsidiary, Sartorius Stedim Data Analytics, the release features significant improvements for applications in biopharmaceutical, pharmaceutical, and other manufacturing industries. Delivering in-depth insights into process performance across the manufacturing network, managerial staff can take evidence-based proactive actions that will help to achieve better timely decisions, ensuring superior manufacturing success.

Active Dashboard 2 provides real-time process information from multivariate SIMCA-online data analysis systems — part of the Umetrics Suite of Data Analytics Solutions. The Active Dashboard 2 software now offers innovative data visualisation options, such as easy self-service visual analytics with cross-filtering to reduce the involvement of data analysis experts; role-based display of relevant information; and the ability to connect to other data sources.
“The improvements in Active Dashboard 2 will help our customers to enhance their competitive advantage – both globally and locally. With in-depth insights into data of their manufacturing processes, they can significantly improve the decision-making process,” said Jonas Elfving, product manager at Sartorius Stedim Data Analytics.
Looking for chemical products? Let suppliers reach out to you!
2026-07-06
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Novo Nordisk Faces a Compliance Test
-
BioNTech’s Founders Turn the Page
-
India’s API Trade Balance Turns Positive
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
Lilly Bets Bigger on China
-
Rising API Costs Threaten Drug Prices
-
Haryana’s Drug Crackdown Gets Massive Public Support State Launches Podcast to Boost Community Involvement
-
Wall Street Predicts New Obesity Pills Will Be Priced Near $1000 Like Wegovy and Zepbound Supply and Competition Pressures Mount
Recommend Reading
-
Glenmark Targets 10–15 Percent CAGR in India by Shifting to High-Margin Drugs AbbVie Deal and New Launches Boost Outlook
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
-
EFSA Reaffirms Safety of E948 Oxygen and E949 Hydrogen in All Foods No Health Risks Detected
-
Indian Pharma Urges US to Exempt Generics as 50 Percent Tariffs Loom National Security Probe Sparks Supply Fears
-
India Issues Final Anti-Dumping Ruling on Chinese TDQ, with Duties Up to US$549 per Ton
-
Sinochem International Acquires Nantong Xingchen for 2.11 Billion Yuan, Rike Chemical Plans Genyuan New Materials Acquisition – The Changing Landscape of Chemical M&A
-
EU Clears Bayer-KWS Sugar Beet Event
-
Supply-Demand Struggle Continues, Acrylic Market Remains Weak
-
Premium Global Chemical Sourcing Requests (24-28 Nov 2025)